RVX Share Price

Open 1.39 Change Price %
High 1.41 1 Day -0.03 -2.08
Low 1.39 1 Week 0.00 0.00
Close 1.41 1 Month 0.09 6.82
Volume 19504 1 Year -0.22 -13.50
52 Week High 2.47
52 Week Low 1.23
RVX Important Levels
Resistance 2 1.43
Resistance 1 1.42
Pivot 1.40
Support 1 1.40
Support 2 1.39
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
ECA 13.14 3.38%
ECA 13.14 3.38%
ECA 13.14 3.38%
More..
TSE Canada Top Gainers Stocks
CXA-B 1.15 228.57%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
GLG 1.21 34.44%
PWC 0.10 25.00%
PWC 0.10 25.00%
AAB 0.15 25.00%
AAB 0.15 25.00%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
MSV 0.77 -14.44%
DNT 0.09 -10.00%
CTU-A 0.19 -9.52%
DEJ 0.14 -6.67%
DEJ 0.14 -6.67%
GUY 3.99 -6.56%
AFN 51.71 -6.47%
AFN 51.71 -6.47%
AFN 51.71 -6.47%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 2
As on 18th Sep 2017 RVX Share Price closed @ 1.41 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.79 & Buy for SHORT-TERM with Stoploss of 1.37 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for September
1st Target up-side 1.48
2nd Target up-side 1.56
3rd Target up-side 1.63
1st Target down-side 1.28
2nd Target down-side 1.2
3rd Target down-side 1.13
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
RVX Latest News
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.